论文部分内容阅读
检测肿瘤雌激素受体(ER)有助于评价乳腺癌的疗效和预后。过去曾用葡聚糖包裹活性炭法(DCC)等测定,但存在费用大及各实验室之间数据差异,更重要的是不能正确预测40～50%ER阳性病例和5～10%ER 阴性病例对内分泌治疗的反应。抗雌激素McAb 问世,为测定ER 开辟了新途径,并为在细胞水平检查受体定位带来希望.本文选择经病理检验证实为原发性乳腺癌的225份标本,用抗ERs 的McAb 以免疫组化(ICA)法检验,对同一肿瘤用DCC 测胞浆受体含量,用酶免疫法(EIA)检验其中108份胞浆受体和100份胞核受体。
Detection of tumor estrogen receptor (ER) helps evaluate the efficacy and prognosis of breast cancer. In the past, dextran-encapsulated activated carbon (DCC) was used for measurement, but there are large costs and data discrepancies between laboratories. More importantly, 40-50% ER-positive cases and 5-10% ER-negative cases cannot be correctly predicted. Response to endocrine therapy. The introduction of anti-estrogen McAb has opened up new ways for the determination of ER, and has provided hope for examining receptor localization at the cellular level. This article selected 225 specimens that had been confirmed by pathological examination as primary breast cancer, using anti-ERs McAb. In the immunohistochemical (ICA) assay, DCC was used to measure cytoplasmic receptor content in the same tumor and 108 of the cytoplasmic receptors and 100 nuclear receptors were examined by enzyme immunoassay (EIA).